Zydus Lifesciences Acquires Assertio (ASRT) for $23.50/Share Cash After Topping Garda Deal

The Deal in One Paragraph

Assertio Holdings, Inc. (NASDAQ: ASRT) has agreed to be acquired by Zydus Worldwide DMCC, a UAE-incorporated subsidiary of Zydus Lifesciences Limited, through an all-cash tender offer at $23.50 per share, followed by a Section 251(h) back-end merger. The acquisition vehicle is Zara Merger Sub Inc., and Zydus Pharmaceuticals (USA) Inc. has signed on as guarantor. Total equity consideration is roughly $166.4 million. The tender offer is required to commence within five business days of the May 13, 2026 merger agreement and will run an initial 20 business days, per the SC TO-C and 8-K filed May 13, 2026. ASRT closed at $23.32, an 0.8% gross spread to the offer.

How We Got Here

This is the third price point in a six-week sequence. On April 8, 2026, Assertio first announced an agreement with Garda Therapeutics — a small Delaware acquisition vehicle led by ex-Secura Bio executives — at $18.00 cash plus one non-tradeable CVR per share. Assertio simultaneously sold its non-Rolvedon brands (Indocin, Sprix, Sympazan, Cambia, Zipsor, Otrexup) to Cosette Pharmaceuticals for $35 million upfront, leaving Rolvedon as the lone product the buyer would inherit.

The original Garda deal included a 20-day window-shop period. Assertio engaged with multiple parties and received a Superior Proposal. On May 1, Garda came back with $21.80 cash, no CVR. The stock then drifted above that offer to $22.15 — the market was pricing optionality on yet another bump. That optionality paid off. The Superior Proposer was Zydus; on May 13, 2026, the Assertio board determined the Zydus offer was superior, Garda declined to match within its matching-rights window, and Assertio terminated the Garda agreement and signed with Zydus the same day. Zydus paid the $5.81 million Garda break fee directly, on top of the $23.50 per share going to Assertio holders.

Who Is Zydus

Unlike Garda, Zydus is a real strategic buyer with a multibillion-dollar balance sheet. Zydus Lifesciences is one of India's largest pharmaceutical companies, with operations in 50 countries. Its U.S. arm, Zydus Pharmaceuticals (USA) Inc., based in Pennington, New Jersey, is the fifth-largest unbranded generic corporation in the U.S. by dispensed prescriptions, with more than 500 SKUs and over 280 ANDA approvals, according to the Association for Accessible Medicines.

Zydus has been pushing into U.S. specialty pharma for a decade — most notably with its 2017 acquisition of Sentynl Therapeutics. The Assertio deal extends that strategy: Rolvedon (eflapegrastim), a long-acting G-CSF for chemotherapy-induced neutropenia, gives Zydus an oncology supportive-care brand and access to Assertio's 170-plus community oncology accounts. The strategic fit is straightforward and that matters for deal certainty: this is not a financial sponsor that can walk if its credit committee blinks.

Why This Deal Looks Different From Garda

Every soft spot in the Garda transaction is now harder.

• Counterparty quality. Garda was two principals plus an $80M Colbeck term loan and a $50M delayed-draw facility. Zydus is a subsidiary of a global pharma operator, with Zydus Pharmaceuticals (USA) Inc. signed on as guarantor for parent's obligations. There is still no financing condition, but the balance sheet behind it is incomparably stronger.
• Tender-and-support agreements. Concurrent with signing, certain beneficial owners executed Support Agreements committing to irrevocably tender. The filing doesn't quantify the percentage covered, but locking up insiders front-loads progress toward the 50% minimum threshold.
• Convertible notes addressed up front. Assertio has $40 million of 6.50% Convertible Notes due 2027 outstanding. The merger agreement requires a concurrent tender and consent solicitation at par plus accrued interest, contingent on the Fundamental Change triggered by the merger. The notes will not become a closing-mechanics overhang.
• Higher switching cost for a fourth bidder. If Assertio walks for another Superior Proposal, it owes Zydus a $6.26 million company termination fee plus reimbursement of the $5.81 million Garda fee Zydus already paid — about $12 million in stacked break costs any new interloper has to look past.

Key Terms

Will This Deal Close?

The pieces line up for a high-probability close at $23.50:

• Board approval and process. Unanimous recommendation. The Assertio board ran a real market test — a public window-shop produced one bump from Garda, and a second, higher Superior Proposal from Zydus. That is meaningful price discovery, not a rubber stamp.
• Financing. No financing condition. Zydus represents in the merger agreement that it has sufficient cash or available lines of credit to fund the transaction, and the U.S. affiliate guarantee backstops parent's obligations.
• Minimum tender. A simple majority. Tender-and-support agreements lock up some baseline already, and arb funds will pile in given the board recommendation and positive spread.
• Regulatory. The deal is sub-$200M and Assertio's press release explicitly says no regulatory approvals are expected. There is no HSR filing required at this size, and Rolvedon is a single specialty product — no competitive overlap with Zydus to attract antitrust scrutiny. A UAE/India acquirer of a U.S. specialty pharma asset would normally raise a CFIUS question, but the SC TO-C does not flag one and Rolvedon is not a sensitive technology.
• Closing Net Cash. The $95M threshold is unchanged from the Garda deal, where it was already considered achievable. The bigger risk is operational drift during pendency, not a structural shortfall.
• Fourth bidder. Possible but unlikely. The ~$12M stack of break fees plus matching rights creates a meaningful hurdle, and the price has already moved 75.8% off the unaffected level. The pool of buyers willing to pay a third bump for a single-product specialty pharma is thin.

Timeline

Deal Structure in Plain English

This is a two-step transaction. First, Zara Merger Sub launches a tender offer for all outstanding ASRT shares at $23.50 cash. If more than 50% of shares are tendered (plus any already owned by purchaser or affiliates), Zara buys those shares and any remaining stockholders are cashed out at the same $23.50 in a back-end merger under Section 251(h) of Delaware corporate law. Section 251(h) lets the parties skip the usual stockholder vote because the tender already cleared a majority threshold. Whether you tender or not, you end up with $23.50 per share — tendering simply speeds up the cash payment.

Stock options with an exercise price below $23.50 get cashed out for the spread. Unvested RSUs vest in full and convert to cash at $23.50. The $40M of 6.50% convertible notes due 2027 are handled in a parallel transaction at par plus accrued interest, removing them as a closing-mechanics issue.

Tax and Broker Logistics for Small Holders

For U.S. taxable holders, tendering produces a normal capital-gain (or loss) event at $23.50 per share — short-term if held under a year, long-term if held longer. There is no foreign withholding to worry about: while the parent acquirer is UAE-incorporated, the consideration is being paid by a Delaware subsidiary to U.S. holders of a U.S.-listed stock, with U.S. payer reporting. Holders in Roth IRAs and other tax-advantaged accounts collect the full $23.50 with no tax friction.

If you plan to tender, watch your broker's internal deadline. Most brokerage firms set their cutoffs one to three business days before the stated tender expiration. Settlement of accepted shares is typically T+1 once Zara declares the offer complete. If you do nothing, you still get $23.50 in the back-end merger — it just lands in your account a few days later than tendered shares.

Risks

• Gross spread is narrow. 0.8% over roughly seven to eight weeks is a single-digit annualized return. If close slips toward the July 12 outside date, the annualized math compresses further. This is a low-risk deal, not a high-return one.
• Closing Net Cash condition. Assertio must maintain at least $95 million of Closing Net Cash. A miss — from operational drift, working capital swings, or unexpected expenses during pendency — would give Zydus an out. The same threshold was deemed achievable under the Garda deal, so the absolute risk is modest, but it is a live condition through close.
• Fourth bidder — low but not zero. If a strategic that didn't surface during the window-shop decides to top $23.50, Zydus has matching rights and Assertio owes ~$12M in stacked break fees. The timeline would slip and gross spreads would whipsaw. Probability is low given the price has already moved 75.8% off the unaffected level.
• Regulatory tail risk. No HSR filing, no CFIUS filing flagged in the SC TO-C, and the press release states no regulatory approvals are expected. A foreign acquirer of a U.S. specialty pharma at this size is unlikely to draw scrutiny, but a CFIUS surprise is the lowest-probability tail worth naming.
• No odd-lot provision disclosed. Small holders don't get a proration bypass. That said, this is a 100% cash buyout with no proration mechanism in the first place — every tendered share gets accepted at $23.50.

The Bottom Line

For existing ASRT holders, this is the outcome the prior post argued was worth waiting for. Sit tight, tender into the Zydus offer when it commences within five business days of May 13, 2026, and collect $23.50 in Q2 2026.

For new buyers, the calculus has flipped from "don't chase the negative spread" to "this is now an ordinary low-risk merger-arb trade." Buying at $23.32 locks in roughly 0.8% gross in seven to eight weeks against a board-recommended, fully financed, strategically guaranteed deal with no regulatory hurdle disclosed. The annualized return is decent but not extraordinary, and arb desks have already compressed it. The play is sized for capital preservation, not heroics.

For anyone who shorted the prior negative spread on the thesis that no second bump would arrive: cover. The optionality the market priced at $22.15 was real, and a third bump from here is a meaningfully lower-probability bet than the second one was.

This analysis is for informational purposes only and does not constitute investment advice. Read the complete filing and consult your own advisors before making any decisions.